Q1 2020 Earnings Forecast for Cooper Companies Inc Issued By Jefferies Financial Group (NYSE:COO)

Cooper Companies Inc (NYSE:COO) – Analysts at Jefferies Financial Group cut their Q1 2020 earnings per share estimates for shares of Cooper Companies in a note issued to investors on Thursday, December 5th. Jefferies Financial Group analyst A. Petrone now forecasts that the medical device company will post earnings of $2.73 per share for the quarter, down from their previous estimate of $2.95. Jefferies Financial Group has a “In-Line” rating and a $330.00 price objective on the stock. Jefferies Financial Group also issued estimates for Cooper Companies’ Q2 2020 earnings at $3.07 EPS, Q4 2020 earnings at $3.54 EPS, FY2020 earnings at $12.78 EPS, FY2021 earnings at $14.08 EPS and FY2023 earnings at $16.95 EPS.

Cooper Companies (NYSE:COO) last issued its quarterly earnings data on Thursday, December 5th. The medical device company reported $3.30 EPS for the quarter, beating the consensus estimate of $3.27 by $0.03. The firm had revenue of $691.60 million during the quarter, compared to the consensus estimate of $683.83 million. Cooper Companies had a net margin of 17.59% and a return on equity of 17.38%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.87 earnings per share.

Several other equities research analysts have also recently weighed in on the company. Northcoast Research reiterated a “buy” rating on shares of Cooper Companies in a report on Tuesday, December 3rd. KeyCorp upped their target price on Cooper Companies from $348.00 to $351.00 and gave the company an “overweight” rating in a report on Wednesday, November 27th. Zacks Investment Research raised Cooper Companies from a “sell” rating to a “hold” rating and set a $325.00 price target for the company in a research note on Wednesday, November 20th. Raymond James dropped their price target on Cooper Companies from $364.00 to $355.00 and set an “in-line” rating for the company in a research note on Friday. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $344.00 price target on shares of Cooper Companies in a report on Friday. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $328.73.

Shares of NYSE:COO opened at $302.26 on Monday. Cooper Companies has a 1 year low of $228.65 and a 1 year high of $344.32. The company has a market cap of $15.23 billion, a PE ratio of 24.47, a P/E/G ratio of 2.23 and a beta of 0.91. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.05 and a quick ratio of 0.59. The stock’s 50-day moving average is $299.21 and its 200 day moving average is $312.26.

In other news, Director Allan E. Rubenstein sold 1,335 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $299.61, for a total value of $399,979.35. Following the completion of the transaction, the director now owns 3,591 shares of the company’s stock, valued at approximately $1,075,899.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.70% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ossiam bought a new position in Cooper Companies in the second quarter worth $25,000. Kings Point Capital Management purchased a new position in Cooper Companies during the second quarter valued at $27,000. NumerixS Investment Technologies Inc bought a new stake in shares of Cooper Companies during the 2nd quarter valued at $34,000. Flagship Harbor Advisors LLC boosted its holdings in shares of Cooper Companies by 100.0% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 156 shares of the medical device company’s stock valued at $46,000 after buying an additional 78 shares in the last quarter. Finally, CSat Investment Advisory L.P. grew its position in shares of Cooper Companies by 105.6% in the 2nd quarter. CSat Investment Advisory L.P. now owns 148 shares of the medical device company’s stock worth $50,000 after buying an additional 76 shares during the period. Institutional investors own 95.35% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Further Reading: What is quantitative easing?

Earnings History and Estimates for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.